首页> 外文期刊>Acta oncologica. >Anxiety and depression in oncology patients; A longitudinal study of a screening, assessment and psychosocial support intervention
【24h】

Anxiety and depression in oncology patients; A longitudinal study of a screening, assessment and psychosocial support intervention

机译:肿瘤患者的焦虑和抑郁;对筛查,评估和社会心理支持干预措施的纵向研究

获取原文
获取原文并翻译 | 示例
       

摘要

Background. Anxiety and depression in cancer patients are associated with poor health-related quality of life (HRQOL). Clinical interventions to detect and support patients with these symptoms need to be developed and evaluated. We investigated the feasibility of screening with the Hospital Anxiety and Depression Scale (HADS) in a clinical oncology setting. In patients with anxiety or depression symptoms (HADS >7) we explored the use of clinical assessment and psychosocial support and described the development of anxiety, depression and HRQOL during a six-month period. Material and methods. Four hundred and ninety-five consecutive patients were screened for anxiety and depression at the time of their first visit at an oncology department (baseline). Half of the patients with HADS >7 on any of the two HADS subscales were referred to clinical assessment and psychosocial support (intervention group, IG) and half received standard care (SCG) using a historical control group design. HADS and EORTC QLQ-C30 were completed at baseline and after one, three and six months. Results. One hundred and seventy-six (36%) of 495 patients had anxiety or depression symptoms at screening, HRQOL at baseline was clearly impaired for them. Thirty-six (43%) of 84 IG patients attended clinical assessment, resulting in subsequent psychosocial support for 20 (24%) of them. In the SCG, only five (5%) patients attended clinical assessment after self referral, two received subsequent psychosocial support. Anxiety and depression decreased and HRQOL increased statistically significantly over time although anxiety was frequent and HRQOL impaired during the entire six month period. There were no differences between the SCG and IG regarding anxiety, depression or HRQOL at any time point. Conclusion. Systematic screening with HADS is feasible for oncology patients in clinical settings; it identifies patients with persistent symptoms and increases referral to clinical assessment and utilisation of psychosocial support.
机译:背景。癌症患者的焦虑和抑郁与健康相关的生活质量(HRQOL)相关。需要开发和评估用于检测和支持具有这些症状的患者的临床干预措施。我们调查了在临床肿瘤学环境中使用医院焦虑抑郁量表(HADS)进行筛查的可行性。对于焦虑或抑郁症状(HADS> 7)的患者,我们探索了临床评估和心理社会支持的使用,并描述了六个月期间焦虑,抑郁和HRQOL的发展。材料与方法。在肿瘤科首次就诊时(基线),对495例连续患者进行了焦虑和抑郁筛查。在两个HADS分量表中任一个的HADS> 7的患者中,一半接受了临床评估和社会心理支持(干预组,IG),一半接受了历史对照组设计的标准护理(SCG)。 HADS和EORTC QLQ-C30在基线以及一个,三个和六个月后完成。结果。 495例患者中有176例(36%)在筛查时出现焦虑或抑郁症状,基线时的HRQOL明显受损。 84名IG患者中有36名(43%)参加了临床评估,随后有20名(24%)获得了社会心理支持。在SCG中,只有五(5%)名患者在自我推荐后参加了临床评估,其中两名接受了随后的社会心理支持。尽管在整个六个月的时间里焦虑不安和HRQOL受损,但焦虑和抑郁随着时间的推移而下降,HRQOL统计学上显着增加。在任何时候,SCG和IG在焦虑,抑郁或HRQOL方面均无差异。结论。使用HADS进行系统筛查对于临床环境中的肿瘤患者是可行的。它可以识别具有持续症状的患者,并增加转诊到临床评估和社会心理支持的利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号